Therefore, interventions which might reduce trastuzumab-mediated cardiac dysfunction could be of benefit to HER2-positive BC patients who are at risk of developing detrimental cardiomyopathy from trastuzumab treatment. Here, ERBB2 is linked to breast cancer.